Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 antibodies are also safe when administered in combination with a variety of systemic therapies (chemotherapy, targeted therapies), as well as with radiotherapy. We summarize preclinical, translational, and preliminary clinical data in support of combination approaches with anti-PD-1/L1 in metastatic breast cancer, focusing on potential mechanisms of synergy, and considerations for clinical practice and future investigation.

阻断程序性死亡 1（抗 PD-1）或其配体（抗 PD-L1）的抗体作为转移性乳腺癌的单一疗法，反应率适中，但通常具有良好的耐受性，并且能够在转移性乳腺癌中产生显着且持久的益处。少数患者。抗 PD-1/L1 抗体与多种全身疗法（化疗、靶向疗法）以及放射疗法联合使用时也是安全的。我们总结了临床前、转化和初步临床数据，以支持与抗 PD-1/L1 联合治疗转移性乳腺癌，重点关注潜在的协同作用机制，以及临床实践和未来研究的考虑因素。